Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Dec 24, 2016
Share this video with anyone and everyone #CancerCure EBC-46 is an experimental drug candidate being studied pre-clinically by the Australian company Ecobiotics (specifically its drug discovery subsidiary Qbiotics). It was discovered through an automated screening process of natural products by selecting increasingly purified fractions of plant extracts, based on their ability to produce the desired activity profile. This is then followed by artificial synthesis of the isolated compound to confirm its chemical structure. EBC-46 is a phorbol ester which, along with other related compounds, acts as a protein kinase C regulator.
The initial lead came from observation that marsupials found the seed of Fontainea picrosperma unpalatable due to an inflammatory chemical present in reasonably high concentrations. This was identified as 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tiglian-3-one.
EBC-46 is an extract from the blushwood berries of Queensland, Australia.